These include low PD-L1 expression on tumor cells and TILs, low tumor mutation burden (TMB) and immune escape using other immune checkpoints in patients with EGFR-mutant NSCLC [13–16]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.